MDxHealth (MDXH) Research & Development (2021 - 2026)

MDxHealth has disclosed Research & Development across 6 years of filings, most recently posting -$2.1 million for Q1 2026.

• Research & Development for Q1 2026 came in at -$2.1 million, up 14.61% year-over-year; the trailing twelve-month figure through Mar 2026 was -$7.4 million (up 31.79% YoY), and the FY2025 annual result was $10.4 million, down 1.91% from the prior year.
• Research & Development came in at -$2.1 million for Q1 2026 at MDxHealth, up from -$3.3 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of -$8045.0 in Q2 2025 to a low of -$3.6 billion in Q2 2022.
• The 5-year median for Research & Development is -$2.1 million (2026), against an average of -$212.6 million.
• Peak annual rise in Research & Development reached 99.95% in 2023, while the deepest fall reached 128.91% in 2023.
• MDxHealth's Research & Development stood at -$799000.0 in 2022, then slumped by 128.91% to -$1.8 million in 2023, then plunged by 52.43% to -$2.8 million in 2024, then fell by 17.54% to -$3.3 million in 2025, then soared by 34.88% to -$2.1 million in 2026.
• The last three Research & Development figures came in at -$2.1 million (Q1 2026), -$3.3 million (Q4 2025), and -$2.0 million (Q3 2025), per Business Quant data.